ImmunityBio Shares Rebound as Company Moves to Resolve FDA Warning on Anktiva Promotion
ImmunityBio Inc. (NASDAQ: IBRX) is bouncing back after previously sliding 20–27% on news that the FDA’s Office of Prescription Drug Promotion issued a warning letter over “misleading” TV and podcast promotions for its bladder cancer drug, Anktiva. The company has confirmed it is reviewing the letter and intends to respond within the FDA’s 15‑day window with corrective steps, which analysts view as a standard compliance process rather than a threat to Anktiva’s approval status.
What the FDA flagged
The warning letter said ImmunityBio’s materials created a “misleading impression” that Anktiva can cure or prevent all cancer, even though it is only approved for BCG‑unresponsive non–muscle‑invasive bladder cancer in combination with BCG. The agency ordered the firm to stop using the TV ad and podcast and warned that failure to correct the issues could lead to legal action, although precedent suggests such cases are typically resolved with labeling and promotional changes.
Analyst stance and medium‑term setup
BTIG reiterated a Buy rating and 13‑dollar price target after the selloff, calling the issue “likely resolvable” and highlighting that Anktiva is generating real commercial revenue with additional data in BCG‑naïve bladder cancer expected in the second half of 2026. Event‑driven research notes that the sharp drop erased roughly 2 billion dollars in market cap and may represent an overreaction to a compliance issue, though a new securities class‑action lawsuit tied to the promotional claims adds headline risk.
Investor angle for IBRX
For IBRX shareholders, the near‑term story hinges on the company’s written response and the FDA’s follow‑up: a clean resolution would support the current rebound, while any indication of tougher enforcement could keep a regulatory overhang on the stock. Longer term, the key value drivers remain Anktiva’s commercial ramp, new geographies such as Macau, updated NCCN guideline support, and pipeline progress in NK‑cell therapies—all of which investors must weigh against heightened scrutiny of the company’s communications.
